StemCell Therapy

The All India Institute of Medical Sciences (AIIMS) has released the details of the entrance exam through which candidates will be shortlisted for admission into BSc and MSc courses. According to the details, AIIMS BSc Nursing, BSc Nursing (Post-Basic) and BSc (paramedical courses) admission entrance exam are scheduled for June 6, 20 and 28.

The exam for the admission to MSc Nursing, MSc Biotechnology and other MSc courses will be held on June 6 and July 4. The registration window for the MSc course will open on December 13 and for the BSc courses on December 12.

Candidates who have passed class 12th exams are eligible for the BSc programs and graduates are eligible for the MSc programs.

For the BSc nursing post-basic course candidates with Diploma in General Nursing and Midwifery from any institution recognized by the Indian Nursing Council and Registration as a nurse, RN, RM (registered nurse, registered midwife) with any State Nursing Council along with 10+2 qualification are eligible to apply.

The registration for both the courses will close on January 16, 2020.

Tags: Aiims Aiims Nursing Exam Aiims Biotechnology Exam Aiims Paramedical Admission Aiims Bsc Nursing Bsc Paramedical Courses

Read this article:
Admission details available for the AIIMS Nursing, Biotechnology and Paramedical admissions - Brainbuxa

Since PDS Biotechnology Corporation (NASDAQ:PDSB) and Axsome Therapeutics Inc. (NASDAQ:AXSM) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation of both companies.

Earnings & Valuation

Demonstrates PDS Biotechnology Corporation and Axsome Therapeutics Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of PDS Biotechnology Corporation and Axsome Therapeutics Inc.

Risk & Volatility

PDS Biotechnology Corporation has a 2.42 beta, while its volatility is 142.00% which is more volatile than Standard and Poors 500. From a competition point of view, Axsome Therapeutics Inc. has a 2.65 beta which is 165.00% more volatile compared to Standard and Poors 500.

Liquidity

PDS Biotechnology Corporations Current Ratio is 5 while its Quick Ratio is 5. On the competitive side is, Axsome Therapeutics Inc. which has a 5.7 Current Ratio and a 5.7 Quick Ratio. Axsome Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to PDS Biotechnology Corporation.

Analyst Ratings

The next table highlights the given recommendations and ratings for PDS Biotechnology Corporation and Axsome Therapeutics Inc.

The consensus target price of PDS Biotechnology Corporation is $8.5, with potential upside of 201.42%. Competitively Axsome Therapeutics Inc. has a consensus target price of $48, with potential upside of 5.66%. The information presented earlier suggests that PDS Biotechnology Corporation looks more robust than Axsome Therapeutics Inc. as far as analyst belief.

Insider & Institutional Ownership

Roughly 28.3% of PDS Biotechnology Corporation shares are owned by institutional investors while 46.3% of Axsome Therapeutics Inc. are owned by institutional investors. About 6.5% of PDS Biotechnology Corporations share are owned by insiders. Comparatively, Axsome Therapeutics Inc. has 2.2% of its share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year PDS Biotechnology Corporation has weaker performance than Axsome Therapeutics Inc.

Summary

On 6 of the 11 factors Axsome Therapeutics Inc. beats PDS Biotechnology Corporation.

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders. The companys product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and Alzheimers disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain. The company was founded in 2012 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Follow this link:
Comparison of PDS Biotechnology Corporation (PDSB) and Axsome Therapeutics Inc. (NASDAQ:AXSM) - The Broch Herald

Crystal market research acknowledges the inclusion of a second report to a Global Biotechnology Market. The report summarizes the players that are perceptible in the Biotechnology market with an exact objective to provide a rationalist and purpose of their unpretentious forces of this current Biotechnology market, as the provincial and product segments are likewise expected at length, bearing in mind the Biotechnology objective to grant a granular example of this economys collapse.

The Biotechnology report expands coverage of business and market trends that are chief. The Biotechnology industry research incorporates require, predictions and classical market data, application information and cost trends, and business stocks. The Biotechnology analysis divides the sector dimensions, by price and volume, dependent on geography and application type.

Get the FREE PDF of this Research Report Now! @https://www.crystalmarketresearch.com/report-sample/HC012294

Continued

Inquiry More about this Research Report Now!: https://www.crystalmarketresearch.com/send-an-enquiry/HC012294

Check Exclusive Discount on this report @https://www.crystalmarketresearch.com/check-discount/HC012294

Contacts Us:

Sherry | APAC Marketing Division: Level 23-1, Premier Suite

Mont Kiara, 50480 Kuala Lumpur

Malaysia

E-mail: sales@crystalmarketresearch.com

Read more from the original source:
New innovative report on Biotechnology Market to Boom In Near Future by Industry Key Players: Merck & Co,Abbott Laboratories,Novo Nordisk - Day...

Shutterstock

China is rapidly gaining on the United States when it comes to creating technology that mitigates disease threats and developing pharmaceuticals faster, and its a phenomenon driven by a philosophy that the state, military, and the private sector are one in the same.

That was the testimony of Tara J. OToole, senior fellow and executive vice president at In-Q-Tel, before the U.S. Senate Armed Services Subcommittee on Emerging Threats and Capabilities. The hearing, Biological Threats to U.S. National Security, examined everything from Chinas push to develop biotechnology infrastructure to luring research scientists away from the United States to work in China.

China has said repeatedly and forcefully, and theyre backing up their words with actions, that they intend to own the biorevolution, OToole said. And they are building the infrastructure, the talent pipeline, the regulatory system, and the financial system they need to do that.

China is partly accomplishing this by combining its internet giants, such as Alibaba, with its biotech companies. The combined strength of these companies research focuses on the industrialization of artificial intelligence in which China is institutionalizing it whereas the United States is only experimenting with it, OToole added.

Chinas goal is to make biotechnology 5 percent of the countrys GDP by 2020. China has changed regulations for its own version of the Food and Drug Administration to be more like that of the United States in order to more easily market to the world. The country has created a talent pipeline that incentivizes its own students to go into the life sciences and bioengineering. China also has at least 20 programs intended to bring scientific talent from the rest of the world.

There are good reasons China is going after the biorevolution: it has the highest incidences of cancer on earth and the population is aging. It also must find an affordable way to deliver health care to a rising middle class.

And China is delivering health care to the world. The country is the largest producer of active pharmaceutical ingredients. However, reliance on foreign pharmaceuticals has national security implications. As many as 80 to 100 percent of critical drugs are manufactured outside the United States. U.S Sen. Gary Peters (D-MI) told the committee that following the 2001 anthrax attacks, the U.S. was dependent on a single foreign source for a broad-spectrum antibiotic to treat anthrax.

To what extent is the U.S. reliant on foreign sources for key drug products and medical supplies such as syringes and needles and other critical medical supplies that we would need to respond to a biological attack today? Peters asked the panel of experts.

The United States is critically dependent on China for several drugs and has been shipping manufacturing capacity to Asia for more than a decade.

There isnt a CEO of a major pharma company that hasnt been recruited by China to build facilities there, OToole said.

To address the drug supply chain, the United States has begun exploring the possibility of using synthetic biology to make active pharmaceutical ingredients, especially in response to epidemics.

If there were a natural pandemic in which the entire world needed drugs, Im sure China, as we would, take care of its own people first. Yet, we dont have the surge capacity to produce enough very common, well-used medicine in time to deal with an epidemic, OToole said.

Thomas Inglesby, director of the Center for Health Security at the Johns Hopkins Bloomberg School of Public Health, told the committee that the U.S. treats medicines too much like commodities that can be sourced for the lowest price somewhere in the world.

In a crisis, everyone in every part of the world would be looking for medicine at the same time, Inglesby said. There should be at least a strategic examination of the kinds of things we must have, and we should consider how to bring some of those medicines back to the U.S. Obviously that cant be done with all medicines. Were an interconnected world. But for national health crises, we should be thinking about making them here.

Part of the problem is that the United States has not done a good job at translating biology to products, OToole said, or building infrastructure for securing and promoting the bioeconomy. Our translational infrastructure for biology is mostly coming from small start-up companies in the private sector, which are the innovation engines for biology, but do not provide the robust infrastructure to manage epidemics, whether deliberate or natural.

The experts made the following recommendations:

* Take on synthetic biology as a national security priority;* Use the National Defense Education Act to improve access to stem education and establish greater scientific careers within the U.S. government;* The contingency fund levels for the Centers for Disease Control and Prevention and USAID should be increased and sustained;* Support and strengthen the militarys infectious disease research laboratories;* Provide strong, coherent leadership at the National Security Council essential for guaranteeing effective oversight, long before a crisis emerges;* The U.S. Department of Agriculture should prioritize stronger crop surveillance, animal wildlife surveillance, more support for animal vaccine development, and more funding for agricultural biodefense overall;* Strongly support the biological weapons convention.

During epidemics, the U.S. should be able to immediately create diagnostics that could be used similarly to a pregnancy test so that people can determine for themselves who is sick and who isnt. Officials should be able to rapidly develop a new vaccine in response to an epidemic, OToole added.

These same tools also apply to diseases that affect agriculture and the U.S. animal supply. More than half of all infections that people contract are spread by animals.

Ill start by acknowledging that mother nature is a really good terrorist, Julie L. Gerberding, co-chair of the Commission on Strengthening Americas Health Security at the Center for Strategic and International Studies, told the committee. China today is experiencing a dreadful outbreak of swine fever that has probably cost the death or culling of at least 50 percent of their entire population of pork which is a major source of protein for people in China. So, this is a major socioeconomic threat to the state of China today and thats mother nature.

Swine fever, however, is not spread to humans, though it has a devastating economic impact. And U.S. farmers are concerned about trade and travel bringing such infectious diseases to this country.

I would say that the first alarming statistic is that we spend probably about 100 times less on agricultural threats than we do on human threats, Inglesby said. I think there are many reasons for this. But one includes a kind of reluctance within the U.S. government to talk about this threat until quite recently.

Continue reading here:
Chinese biotechnology dominates US Senate hearing on biological threats - Homeland Preparedness News

On the second floor of the Pennovation Center, Strella Biotechnology is hard at work turning their student-led startup into a full-fledged company thats ready to make a major impact in the agricultural sector.

May graduates Katherine Sizov and Malika Shukurova, respectively the CEO and head of R&D at Strella, share a 2019 Presidents Innovation Prize, which includes $100,000 of financial support, a $50,000 living stipend for both awardees, and a year of dedicated co-working and lab space at the Pennovation Center. The alumnae and their company are now poised to take on the challenge of $1 trillion worth of food waste.

Strellas biosensors are designed to give packers real-time data on how ripe their fruits are while being stored between harvesting and selling. Using bio-inspired sensors that measure the ethylene gas produced by fruits as they ripen, Strella successfully hacked the fruit to create their patent-pending biosensors. Now, only six months after graduation, Strella has six paying customers and is aiming for $100,000 in sales by the end of the season.

Beyond the work needed to deploy their first paid product, Strella also has a clear view of what needs to be done for future progress of the company. This means running experiments in the lab to refine their current sensors while conducting other experiments that will help the company be able to monitor other types of fresh foods. Its a job that Shukurova says involves a lot of multitasking and requires an all-hands approach to problem solving.

We set up experiments that run for several days, and during that period we work on different tasks. I prepare for the next set of experiments, Jacob [Jordan] and Katherine travel to our customers to deploy sensors, and Zuyang [Liu]]works on IoT [Internet of Things]. At the end of the day we all come together to discuss results and future plans, says Shukurova about their companys work flow.

The company is also finding ways to expand their technology onto individual pallets in retail settings, which represents a huge untapped market for managing food waste. That opportunity, from a numbers perspective, is far greater than the current packing market were working in, so were hoping to make an impact as we move into that space as well, says Sizov.

During the next six months, the team will be busy analyzing the data collected by their deployed sensors and gearing up for a new round of fundraising. Looking further ahead, Strella aims to increase sales in their initial market, conduct research and development on individual pallet-level sensors, and begin active partnerships with larger retailers to help optimize their supply chains.

Sizov admits that Strella has an ambitious timeline but that the team is looking forward to the challenge. Working alongside Jordan, Liu, and Shukurova, Sizov says that Strella already has its own culture of sorts. None of us have ever had a business before, and learning how to create culture within a group, how to work together as a team, and how to not get tired of each other because we spend so much time together, has been an interesting challenge, says Sizov.

Their lab and coworking space at Pennovation has allowed Strella to stay connected with Penns innovator community while also providing lab facilities and resources needed to continue their work on their sensors. Strella has two lab benches and a fume hood, access to shared lab equipment, and plenty of space to house their prototypes, all provided for free as part of their Innovation Prize.

Theyve also been able to stay well-connected to the Penn community as a whole, traveling regularly to campus to meet with faculty, including weekly meetings with their mentorJeffrey Babin. We are not out of [the] Penn mindset, says Shukurova. We dont have to worry about exams, but were still on campus and were still involved with the faculty.

Babin says that Strella is one of the most exciting companies that Ive seen come out of Penn and that the company is in a strong position to make some significant impact on the food supply chain. One of the things thats been strong since the beginning was having an expanded vision: Not just on product development, but getting a customer, he says. They have a really strong sense of whats required to acquire a customer, what the next steps are, and growing both within the initial customer base while expanding to other elements.

When asked what advice they would give to would-be entrepreneurs, Shukurovas advice is to take it as a journey. She encourages students who have an idea to share their thoughts with others to get feedback before beginning any startup endeavor. Talk to more peopledont limit yourself to 10 people, or 20 people, talk to hundreds of people, she says.

Sizov says that the experience of running a startup has been a great learning experience, one that is far less risky than might seem at first, especially thanks to the Innovation Prize. If youre just following your passion, thats not a risk. Youre not putting aside your career, she says. Everything we learn at Strella is directly teaching us how to be better and smarter individuals.

Jeffrey Babin is a practice professor and associate director of the Engineering Entrepreneurship Program in the School of Engineering and Applied Science.

Homepage photo: Presidents Innovation Prize winners Katherine Sizov and Malika Shukurova (front) doing R & D to help design new versions of their fruit-hackingbiosensors at the Pennovation center.

Original post:
Strella Biotechnology tackles food waste by 'hacking the fruit' - Penn: Office of University Communications

Aravive Inc (ARAV) is near the top in its industry group according to InvestorsObserver. ARAV gets an overall rating of 81. That means it scores higher than 81 percent of stocks. Aravive Inc gets a 98 rank in the Biotechnology industry. Biotechnology is number 87 out of 148 industries.

Click Here to get the full Stock Score Report on Aravive Inc (ARAV) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 81 means the stock is more attractive than 81 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Aravive Inc (ARAV) stock has fallen -15.53% while the S&P 500 has gained 0.17% as of 10:44 AM on Wednesday, Nov 27. ARAV is lower by -$1.46 from the previous closing price of $9.40 on volume of 1,348,672 shares. Over the past year the S&P 500 has risen 17.28% while ARAV has gained 43.06%. ARAV lost -$6.00 per share the over the last 12 months.

To screen for more stocks like ARAV click here.

View post:
Where Does ARAV Stock Rank in the Biotechnology Industry? - InvestorsObserver

I had one of those way-cool moments and what I now call the most memorable experience of my life this past week in Mombasa, Kenya.

It all started in late October, when I received an invitation from the African Agricultural Technology Foundation (AATF) to attend the Open Forum on Agricultural Biotechnology in Africa (OFAB) 2019 Media Awards on Nov. 21.

The AATF is a nonprofit organization focused on providing smallholder farmers in sub-Saharan Africa with practical technology solutions capable of addressing their farm productivity constraints and improving their livelihoods. One of its initiatives is OFAB, which works to enhance knowledge-sharing and awareness on agricultural biotechnology across seven African countries: Kenya, Tanzania, Ghana, Ethiopia, Uganda, Nigeria and Burkina Faso.

Exactly 18 days after receiving AATFs invitation, OFAB-Nigeria named me best agricultural biotechnology reporter in the print and online category and overall journalist of the year for my entry GMO debate affects public sentiment in Nigeria. I understood then that AATFs email was but a confirmation that I would be representing Nigeria at the continental level of the media awards in Mombasa.

As is typical of Mombasas fluctuating tropical climate, it was a relatively cool evening when the crme de la crmeof Africas science journalists joined scientists and policymakers from the seven OFAB countries for the media awards ceremony at the Sarova Whitesands Hotel. Dressed in a light-blue striped, knee-level kaftan, a black cap and a green-white-green traditional scarf, I joined the throng of people dressed primarily in their own colorful national and traditional garb.

Eugenia Abu, a veteran multimedia journalist who spoke on behalf of the panel of judges, said the awards were intended to acknowledge excellence in science journalism. We congratulate all the winners and urge for more synergy between science and journalism to enable AATF and OFAB to promote better lives for small-holder farmers on the continent through technology, Abu said.

As the crowd cheered, I heard my name announced as the winner in the print and online category. Visibly excited, but also bewildered, I began making my way to the stage. Many thoughts raced through my head at that auspicious moment, such as why are farmers in Africa slow in adopting agricultural innovations? I recalled that in developing my award-winning piece, I had interviewed many people on the streets who did not know what genetically modified organisms (GMOs) are or understand the term biotechnology.

Moreover, I thought again, studies have shown that our current trajectory for crop yields is insufficient to nourish the worlds population by 2050. Hence, with the worlds growing population and climate change, theres a need for greater and more consistent food production around the globe. This is particularly true in Africa, which is projected to hit 2.2. billion people by 2050.

Africa cannot achieve food sufficiency or realize its dream of becoming the food basket of the world without farmers having access to improved seeds, agricultural tools and technology on their farms. Thus journalists have a critical role to play in informing and educating African farmers and consumers about advances in modern agriculture and ensuring that farmers have access to options, including biotechnology. My aim is to connect these scientific innovations and technology to farmers in Africa through better communication.

On Nov. 23, as my Ethiopian Airlines return flight touched down in Abuja, I was filled with a sense of satisfaction for all that had transpired in Mombasa as well as nostalgia for the incredibly talented African journalists with whom I had shared the homey hospitality of the Sarova Whitesands Hotel for the past three days.

As a science journalist, I also felt a strong reconfirmation of my belief that Africas agriculture needs science and technology more than any other continent in the world. Consequently, African journalists must understand and believe in the potential of science and technology so as to report, write and communicate science accurately and spur economic development on the continent.

Asante!

Abdullahi Tsanni is a Nigerian science writer and Alliance for Science contributor.

Read the rest here:
Using media to connect African farmers with scientific innovation and technology - Alliance for Science

Robert W. Baird began coverage on shares of Vir Biotechnology (NYSE:VIR) in a report released on Wednesday, November 13th, The Fly reports. The firm issued a neutral rating on the stock.

Other analysts have also issued reports about the company. Cowen assumed coverage on Vir Biotechnology in a report on Tuesday, November 5th. They set an outperform rating on the stock. Goldman Sachs Group began coverage on Vir Biotechnology in a research note on Tuesday, November 5th. They issued a buy rating and a $37.00 price objective on the stock. Barclays began coverage on Vir Biotechnology in a research note on Tuesday, November 5th. They issued an overweight rating and a $25.00 price objective on the stock. Finally, JPMorgan Chase & Co. began coverage on Vir Biotechnology in a research note on Tuesday, November 5th. They issued an overweight rating and a $25.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Vir Biotechnology currently has an average rating of Buy and an average target price of $29.00.

VIR stock traded up $0.07 during trading hours on Wednesday, hitting $11.90. 101,085 shares of the stock were exchanged, compared to its average volume of 164,664. Vir Biotechnology has a 12 month low of $11.65 and a 12 month high of $16.50.

Vir Biotechnology (NYSE:VIR) last posted its quarterly earnings data on Tuesday, November 19th. The company reported ($4.60) earnings per share for the quarter, missing the consensus estimate of ($3.71) by ($0.89). The business had revenue of $1.40 million during the quarter.

In other Vir Biotechnology news, major shareholder Endurance (Cayman) Ltd Svf bought 950,000 shares of the companys stock in a transaction on Wednesday, October 16th. The stock was acquired at an average price of $14.22 per share, for a total transaction of $13,509,000.00. Also, insider Abu Dhabi Investment Authority bought 1,000,000 shares of the companys stock in a transaction on Wednesday, October 16th. The shares were acquired at an average price of $14.41 per share, with a total value of $14,410,000.00.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.

Further Reading: What are the qualifications of a portfolio manager?

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post:
Vir Biotechnology (NYSE:VIR) Coverage Initiated by Analysts at Robert W. Baird - TechNewsObserver

Global Biotechnology Marketis expected to grow at a CAGR of 14% to reach US$ 1,254.1 million in 2024. The growth is coupled with rising demand of modern and innovative technologies such as DNA sequencing, recombinant technology, fermentation, tissue engineering. Further, rising demand for food to meet the need of ever increasing population and scarce availability of non-renewable natural resources also expected to drive the biotechnology market. Application of Genetic engineering and Genetic Modification (GM) processes to agricultural food products also expected to drive the business growth. Furthermore, decreasing prices of DNA sequencing technologies will encourage R&D activities to better understand genetic variations and develop therapeutic solutions.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/10844

Moreover, development of novel techniques and their implementation by the organisation by collaborating with the other participants will drive the Global Biotechnology Market. Further, increasing demand for therapeutic and diagnostic solutions on principles of red biotechnology, DNA sequencing, and recombinant technology is expected to drive the Global Biotechnology Market through 2024. Increasing prevalence of diseases such as hepatitis B, cancer, and other orphan disorders is also expected to fuel demand in the forecast period.

In 2017, North America dominated the overall market. The market growth is driven by the increasing R&D investments relating to new drug discovery and development. U.S. held highest market in North America due to increasing level of per capita spending on healthcare than other countries and has a high growth rate amongst other countries. According to the estimates published by OECD Health Statistics in 2014, it has been estimated that in 2012, U.S. spent nearly 16.9% of its GDP towards healthcare expenditure, which is the highest. The fact supports the estimated share of Global Biotechnology Market.

Asia Pacific is expected to have higher growth rate in the forecast period owing to the presence of patient awareness, rapidly improving healthcare infrastructure, and rising healthcare expenditure levels in the emerging markets. Global Biotechnology Market include the developing economies of China and India.

In 2017, nanobiotechnology held the highest market share. The Global Biotechnology Market growth is driven by fermentation and cell-based assay segments owing to rising R&D initiatives by various biotechnological and pharmaceutical companies.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/10844

Global Biotechnology Market

Market Segmentation By Technologyo DNA Sequencingo Nanobiotechnologyo Tissue engineering and Regenerationo Fermentationo Cell Based Assayo PCR Technologyo Chromatography Marketo Others

By Applicationso Healtho Food & Agricultureo Natural Resources & Environmento Industrial Processingo Bioinformaticso Others

The above data will be provided for following regions/countries from 2013-2024 (USD Million)

North Americao U.S.o Canada

Europeo Germanyo UKo Franceo Spaino Italy

Asia Pacifico Chinao Indiao Japano Australia

Latin Americao Argentinao Brazilo Mexico

Middle East and Africao South Africao Saudi Arabia

MAJOR TOC OF THE REPORT

Chapter One: Biotechnology Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Biotechnology Market Competition, by Players

Chapter Four: Global Biotechnology Market Size by Regions

Chapter Five: North America Biotechnology Revenue by Countries

Chapter Six: Europe Biotechnology Revenue by Countries

Chapter Seven: Asia-Pacific Biotechnology Revenue by Countries

Chapter Eight: South America Biotechnology Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Biotechnology by Countries

Chapter Ten: Global Biotechnology Market Segment by Type

Chapter Eleven: Global Biotechnology Market Segment by Application

Chapter Twelve: Global Biotechnology Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Biotechnology Market Report at:https://www.maximizemarketresearch.com/market-report/global-biotechnology-market/10844/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Read more here:
Global Biotechnology Market : North America Is Expected To Account For Higher Market Share Of More Than 45% Driven By Increasing Investment In Us On...

PRINCETON, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that Lauren V. Wood, M.D., Chief Medical Officer of PDS Biotechnology, has been selected to deliver an oral presentation on the Companys novel T-cell activating immunotherapy platform, Versamune, at the World Vaccine & Immunotherapy Congress West Coast 2019, taking place on December 2-5, 2019 in San Francisco, CA.

Details for the presentation are below:

Presentation Title: Versamune: A Novel T-cell Activating Immunotherapy PlatformTopic: Engaging T-Cells, Cancer Antibodies, and CombinationsPresenter: Dr. Lauren V. Wood, Chief Medical Officer, PDS BiotechnologyDate: Wednesday, December 4, 2019Time: 3:00pm PST

The Versamune platform is PDS Biotechs proprietary, synthetic lipid-based T-cell activating platform, which works by facilitating several critical immunological pathways. Versamunes mechanism of action involves the effective cross-presentation of tumor antigens via the MHC Class I and Class II pathways to prime tumor-specific CD8+ and CD4+ T-cells as well the potent up-regulation of Type 1 interferon genes within the lymph nodes, promoting effective T-cell migration, activation and proliferation. These mechanisms promote strong in-vivo induction of polyfunctional tumor-targeting CD8+ killer T-cells. Versamunes activation specifically of type 1 interferons coupled with the lack of significant systemic cytokine release results in a highly favorable safety profile that has potential uses in combination with checkpoint inhibitors and other therapeutic agents. In a phase 1 human clinical trial PDS Biotechnologys lead Versamune-based immunotherapy exhibited potent antigen-specific CD8+ T-cell induction with an average of over 20-fold increase in the blood circulation within 14 days of treatment. The strong T-cell induction also resulted in complete regression of lesions in the majority of treated cervical intraepithelial neoplasia (CIN) patients. The ability to induce high levels of CD8+ killer T-cells in vivo has resulted in potent synergy with checkpoint inhibitors in preclinical studies. Upcoming phase 2 clinical trials to confirm the unique synergy will also be presented.

About PDS Biotechnology

PDS Biotechnology is a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology platform. The Versamune platform effectively delivers tumor-specific antigens for in-vivo uptake and processing, while also activating a critical immunological pathway, the type 1 interferon pathway, thus resulting in the production of potent tumor-specific killer T-cells. Using Versamune, PDS Biotechnology is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors. PDS Biotechnologys pipeline combines the Versamune technology with tumor-specific antigens across several cancer types. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101

PDS Biotechnologys lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers. In partnership with Merck and the National Cancer Institute (NCI), PDS Biotechnology is advancing PD0101 to Phase 2 studies in head and neck cancer and in HPV-related advanced cancer.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the Company) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Companys management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, anticipate, plan, likely,believe,estimate,project,intend,and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability of the Company to integrate Edge and PDS Biotechnology following the merger; the Companys ability to protect its intellectual property rights; competitive responses to the completion of the merger; potential adverse reactions or changes to business relationships resulting from the completion of the merger;the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings; the timing for the Company or its partners to initiate the planned clinical trials for its lead assets, PDS0101 and PDS0102; the Companys interpretation of the results of its Phase 1 trial for PDS0101 and whether such results are sufficient to support additional trials or the future success of such trials;the successful implementation of the Companys research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Companys interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Companys product candidates; the acceptance by the market of the Companys product candidates, if approved;the timing of and the Companys ability to obtain and maintainU.S. Food and Drug Administrationor other regulatory authority approval of, or other action with respect to, the Companys product candidates;and other factors, including legislative, regulatory, political and economic developmentsnot within the Companys control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Companys annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Story continues

Read this article:
PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 - Yahoo Finance

REPORTING FOR 2019-11-28 | WCX19.ORG: We have done an in-depth analysis of how PDSB has been trading over the last 2 weeks and the past day especially. On its latest session, PDS Biotechnology Corporation (NASDAQ:PDSB) opened at 2.22, reaching a high of 2.38 and a low of 2.1007 before closing at a price of 2.27. There was a total volume of 37786.

VOLUME INDICATORS FOR PDS BIOTECHNOLOGY CORPORATION (NASDAQ:PDSB): We saw an accumulation-distribution index of 7.27226, an on-balance volume of -2.08, chaikin money flow of 2.49125 and a force index of 1e-05. There was an ease of movement rating of 0.0024, a volume-price trend of -1.16026 and a negative volume index of 1000.0.

VOLATILITY INDICATORS FOR PDS BIOTECHNOLOGY CORPORATION (NASDAQ:PDSB): We noted an average true range of 0.2508, bolinger bands of 2.11962, an upper bollinger band of 2.06108, lower bollinger band of 2.1007, a bollinger high band indicator of 1.0, bollinger low band indicator of 1.0, a central keltner channel of 2.23357, high band keltner channel of 2.07357, low band keltner channel of 2.39357, a high band keltner channel indicator of 1.0 and a low band keltner channel indicator of 1.0. There was a donchian channel high band of 2.1007, a donchian channel low band of 2.1007, a donchian channel high band indicator of 1.0, and a donchian channel low band indicator of 1.0.

TREND INDICATORS FOR PDS BIOTECHNOLOGY CORPORATION (NASDAQ:PDSB): We calculated a Moving Average Convergence Divergence (MACD) of -0.00046, a MACD signal of -0.00026, a MACD difference of -0.00021, a fast Exponential Moving Average (EMA) indicator of 2.1007, a slow Exponential Moving Average (EMA) indicator of 2.1007, an Average Directional Movement Index (ADX) of unknown, an ADX positive of 20.0, an ADX negative of 20.0, a positive Vortex Indicator (VI) of 1.0, a negative VI of 1.0, a trend vortex difference of 0.09678, a trix of -42.69843, a Mass Index (MI) of 1.0, a Commodity Channel Index (CCI) of -66.66667, a Detrended Price Oscillator (DPO) of 2.36666, a KST Oscillator (KST) of -529.76734 and a KST Oscillator (KST Signal) of -529.76734 (leaving a KST difference of -1.1584). We also found an Ichimoku rating of 2.3, an Ichimoku B rating of 2.3, a Ichimoku visual trend A of 4.40959, an Ichimoku visual trend B of 3.78933, an Aroon Indicator (AI) up of 4.0 and an AI indicator down of 4.0. That left a difference of -4.0.

MOMENTUM INDICATORS FOR PDS BIOTECHNOLOGY CORPORATION (NASDAQ:PDSB): We found a Relative Strength Index (RSI) of 50.0, a Money Flow Index (MFI) of 34.08787, a True Strength Index (TSI) of -100.0, an ultimate oscillator of -13.38052, a stochastic oscillator of 174.5625, a stochastic oscillator signal of 174.5625, a Williams %R rating of 74.5625 and an awesome oscillator of -0.00285.

RETURNS FOR PDS BIOTECHNOLOGY CORPORATION (NASDAQ:PDSB): There was a daily return of -52.97673, a daily log return of -0.99027 and a cumulative return of -0.98539.

What the heck does all of this mean? If you are new to technical analysis, the above may be gibberish to you, and thats OK (though we do advise learning these things). The bottom line is that AS OF 2019-11-28 (if you are reading this later, the analysis will be out of date), here is what our deep analysis of technical indicators are telling us for PDS Biotechnology Corporation (NASDAQ:PDSB)

DISCLAIMER: We are not registered investment advisers and the above analysis should be taken at face value only. We strongly advise against buying or selling PDS Biotechnology Corporation (NASDAQ:PDSB) based solely on our analysis above, and are not responsible for any losses that you may incur if you choose make any investment decisions based on the above.

The rest is here:
PDS Biotechnology Corporation (NASDAQ:PDSB): The Good, The Bad, The Ugly (2019-11-28) - WCX19

DUBLIN, Nov. 28, 2019 /PRNewswire/ -- The "Genome Editing Services Market-Focus on CRISPR 2019-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographical regions.

Currently, there is an evident increase in demand for complex biological therapies (including regenerative medicine products), which has created an urgent need for robust genome editing techniques. The biopharmaceutical pipeline includes close to 500 gene therapies, several of which are being developed based on the CRISPR technology.

Recently, in July 2019, a first in vivo clinical trial for a CRISPR-based therapy was initiated. However, successful gene manipulation efforts involve complex experimental protocols and advanced molecular biology centered infrastructure. Therefore, many biopharmaceutical researchers and developers have demonstrated a preference to outsource such operations to capable contract service providers.

Consequently, the genome editing contract services market was established and has grown to become an indispensable segment of the modern healthcare industry, offering a range of services, such as gRNA design and construction, cell line development (involving gene knockout, gene knockin, tagging and others) and transgenic animal model generation (such as knockout mice). Additionally, there are several players focused on developing advanced technology platforms that are intended to improve/augment existing gene editing tools, especially the CRISPR-based genome editing processes.

Given the rising interest in personalized medicine, a number of strategic investors are presently willing to back genetic engineering focused initiatives. Prevalent trends indicate that the market for CRISPR-based genome editing services is likely to grow at a significant pace in the foreseen future.

Report Scope

One of the key objectives of the report was to evaluate the current opportunity and the future potential of CRISPR-based genome editing services market. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030.

In addition, we have segmented the future opportunity across [A] type of services offered (gRNA construction, cell line engineering and animal model generation), [B] type of cell line used (mammalian, microbial, insect and others) and [C] different geographical regions (North America, Europe, Asia Pacific and rest of the world).

To account for the uncertainties associated with the CRISPR-based genome editing services market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Topics Covered

1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION3.1. Context and Background3.2. Overview of Genome Editing3.3. History of Genome Editing3.4. Applications of Genome Editing3.5. Genome Editing Techniques3.5.1. Mutagenesis3.5.2 Conventional Homologous Recombination3.5.3 Single Stranded Oligo DNA Nucleotides Homologous Recombination3.5.4. Homing Endonuclease Systems (Adeno Associated Virus System)3.5.5. Protein-based Nuclease Systems3.5.5.1. Meganucleases3.5.5.2. Zinc Finger Nucleases3.5.5.3. Transcription Activator-like Effector Nucleases3.5.6. DNA Guided Systems3.5.6.1. Peptide Nucleic Acids3.5.6.2. Triplex Forming Oligonucleotides3.5.6.3. Structure Guided Endonucleases3.5.7. RNA Guided Systems3.5.7.1. CRISPR-Cas93.5.7.2. Targetrons3.6. CRISPR-based Genome Editing3.6.1. Role of CRISPR-Cas in Adaptive Immunity in Bacteria3.6.2. Key CRISPR-Cas Systems3.6.3. Components of CRISPR-Cas System3.6.4. Protocol for CRISPR-based Genome Editing3.7. Applications of CRISPR3.7.1. Development of Therapeutic Interventions3.7.2. Augmentation of Artificial Fertilization Techniques3.7.3. Development of Genetically Modified Organisms3.7.4. Production of Biofuels3.7.5. Other Bioengineering Applications3.8. Key Challenges and Future Perspectives

4. CRISPR-BASED GENOME EDITING SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE4.1. Chapter Overview4.2. CRISPR-based Genome Editing Service Providers: Overall Market Landscape4.2.3. Analysis by Type of Service Offering4.2.4. Analysis by Type of gRNA Format4.2.5. Analysis by Type of Endonuclease4.2.6. Analysis by Type of Cas9 Format4.2.7. Analysis by Type of Cell Line Engineering Offering4.2.8. Analysis by Type of Animal Model Generation Offering4.2.9. Analysis by Availability of CRISPR Libraries4.2.10. Analysis by Year of Establishment4.2.11. Analysis by Company Size4.2.12. Analysis by Geographical Location4.2.13. Logo Landscape: Distribution by Company Size and Location of Headquarters

5. COMPANY COMPETITIVENESS ANALYSIS5.1. Chapter Overview5.2. Methodology5.3. Assumptions and Key Parameters5.4. CRISPR-based Genome Editing Service Providers: Competitive Landscape5.4.1. Small-sized Companies5.4.2. Mid-sized Companies5.4.3. Large Companies

6. COMPANY PROFILES6.1. Chapter Overview6.2. Applied StemCell6.2.1. Company Overview6.2.2. Service Portfolio6.2.3. Recent Developments and Future Outlook6.3. BioCat6.4. Biotools6.5. Charles River Laboratories6.6. Cobo Scientific6.7. Creative Biogene6.8. Cyagen Biosciences6.9. GeneCopoeia6.10. Horizon Discovery6.11. NemaMetrix6.12. Synbio Technologies6.13. Thermo Fisher Scientific

7. PATENT ANALYSIS7.1. Chapter Overview7.2. Scope and Methodology7.3. CRISPR-based Genome Editing: Patent Analysis7.3.1. Analysis by Application Year and Publication Year7.3.2. Analysis by Geography7.3.3. Analysis by CPC Symbols7.3.4. Emerging Focus Areas7.3.5. Leading Players: Analysis by Number of Patents7.4. CRISPR-based Genome Editing: Patent Benchmarking Analysis7.4.1. Analysis by Patent Characteristics7.5. Patent Valuation Analysis

8. ACADEMIC GRANT ANALYSIS8.1. Chapter Overview8.2. Scope and Methodology8.3. Grants Awarded by the National Institutes of Health for CRISPR-based8.3.1. Year-wise Trend of Grant Award8.3.2. Analysis by Amount Awarded8.3.3. Analysis by Administering Institutes8.3.4. Analysis by Support Period8.3.5. Analysis by Funding Mechanism8.3.6. Analysis by Type of Grant Application8.3.7. Analysis by Grant Activity8.3.8. Analysis by Recipient Organization8.3.9. Regional Distribution of Grant Recipient Organization8.3.10. Prominent Project Leaders: Analysis by Number of Grants8.3.11. Emerging Focus Areas8.3.12. Grant Attractiveness Analysis

9. CASE STUDY: ADVANCED CRISPR-BASED TECHNOLOGIES/SYSTEMS AND TOOLS9.1. Chapter Overview9.2. CRISPR-based Technology Providers9.2.1. Analysis by Year of Establishment and Company Size9.2.2. Analysis by Geographical Location and Company Expertise9.2.3. Analysis by Focus Area9.2.4. Key Technology Providers: Company Snapshots9.2.4.1. APSIS Therapeutics9.2.4.2. Beam Therapeutics9.2.4.3. CRISPR Therapeutics9.2.4.4. Editas Medicine9.2.4.5. Intellia Therapeutics9.2.4.6. Jenthera Therapeutics9.2.4.7. KSQ Therapeutics9.2.4.8. Locus Biosciences9.2.4.9. Refuge Biotechnologies9.2.4.10. Repare Therapeutics9.2.4.11. SNIPR BIOME9.2.5. Key Technology Providers: Summary of Venture Capital Investments9.3. List of CRISPR Kit Providers9.4. List of CRISPR Design Tool Providers

10. POTENTIAL STRATEGIC PARTNERS10.1. Chapter Overview10.2. Scope and Methodology10.3. Potential Strategic Partners for Genome Editing Service Providers10.3.1. Key Industry Partners10.3.1.1. Most Likely Partners10.3.1.2. Likely Partners10.3.1.3. Less Likely Partners10.3.2. Key Non-Industry/Academic Partners10.3.2.1. Most Likely Partners10.3.2.2. Likely Partners10.3.2.3. Less Likely Partners

11. MARKET FORECAST11.1. Chapter Overview11.2. Forecast Methodology and Key Assumptions11.3. Overall CRISPR-based Genome Editing Services Market, 2019-203011.4. CRISPR-based Genome Editing Services Market: Distribution by Regions, 2019-203011.4.1. CRISPR-based Genome Editing Services Market in North America, 2019-203011.4.2. CRISPR-based Genome Editing Services Market in Europe, 2019-203011.4.3. CRISPR-based Genome Editing Services Market in Asia Pacific, 2019-203011.4.4. CRISPR-based Genome Editing Services Market in Rest of the World, 2019-203011.5. CRISPR-based Genome Editing Services Market: Distribution by Type of Services, 2019-203011.5.1. CRISPR-based Genome Editing Services Market for gRNA Construction, 2019-203011.5.2. CRISPR-based Genome Editing Services Market for Cell Line Engineering, 2019-203011.5.3. CRISPR-based Genome Editing Services Market for Animal Model Generation, 2019-203011.6. CRISPR-based Genome Editing Services Market: Distribution by Type of Cell Line, 2019-203011.6.1. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines, 2019-203011.6.2. CRISPR-based Genome Editing Services Market for Microbial Cell Lines, 2019-203011.6.3. CRISPR-based Genome Editing Services Market for Other Cell Lines, 2019-2030

12. SWOT ANALYSIS12.1. Chapter Overview12.2. SWOT Analysis12.2.1. Strengths12.2.2. Weaknesses12.2.3. Opportunities12.2.4. Threats12.2.5. Concluding Remarks

13. EXECUTIVE INSIGHTS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/78rwbq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/genome-editing-services-world-markets-to-2030-focus-on-crispr---the-most-popular-genome-manipulation-technology-tool-300966100.html

SOURCE Research and Markets

Excerpt from:
Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool - P&T Community

Ailsa Craig of the International Biotechnology Trust

Passive equity products have become popular over the past decade as it has become easier and cheaper to track the performance of an index.

While this is a relatively low cost and straightforward way to access stocks and shares, active management remains the preferred choice for certain sectors.

We believe biotechnology is one such example. This industry often experiences high levels of binary risk.

Polar Capital: Healthcare headwinds short term in the US

The value of a biotechnology company can be significantly affected by the results of a single clinical trial or regulatory decision.

For example, in March 2019 Biogen announced it was halting the final phase of clinical trial for a drug known as aducanumab, which was designed to slow the progress of Alzheimer's disease. The share price fell 30% on the news.

If an investor buys a passive product that tracks a biotechnology index, there is no way to mitigate this type of individual stock risk.

An active manager can, however, sidestep this danger by selling out of the stock before the results of the trial are announced, therefore preserving capital.

The manager can then decide whether to reinvest or to allocate elsewhere once the results have been announced.

The biotechnology index is weighted by market capitalisation, giving it a significant exposure to the larger, well-established companies.

These firms are, however, often growing more slowly than smaller, more innovative companies.

Understanding the 'technological revolution in healthcare'

As an active manager does not have to mirror the reference benchmark, they can build a portfolio with a greater exposure to these faster growing firms.

It is also easier to implement an ethical investment strategy through an active manager.

For example, many investors want to avoid those companies that have profited from the opioid crisis.

Unless exchanged-traded fund providers exclude these firms from their benchmark index, this is impossible to do using a passive product.

Managing binary event risk and allocating a higher proportion of the portfolio to faster-growing biotechnology stocks has enabled active managers to outperform the benchmark.

Ailsa Craig is investment manager of the International Biotechnology Trust

Active management allows a manager to allocate a greater proportion of their portfolio to faster growing companies

It's easier for active managers to exclude stocks which do not match investors' ethical considerations.

Actively managed funds cost more than passively managed products, but the difference in price is not that significant

Actively managed funds come with manager risk

Excerpt from:
Sidestepping danger in the biotech sector - Investment Week

NEW YORK, Nov. 19, 2019 /PRNewswire/ --Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Barclay "Buck" A. Phillips, an established life sciences executive, investor and entrepreneur, to its Board of Directors, effective November 14, 2019. With this addition, Immunic's Board will total seven members.

"Buck's decades of relevant experience in the biotechnology sector, both as a Chief Financial Officer and investor, will add a unique perspective to our Board," stated Duane Nash, M.D., J.D., M.B.A., Chairman of the Board of Directors of Immunic. "We look forward to leveraging his significant expertise in the areas of financing strategy, capital markets, business development, and others, which he has garnered during his successful career as an executive and board member for multiple, Nasdaq-listed life science companies. Buck's addition to our team reflects our desire to build the Board during a time of continued clinical progress and we look forward to his contributions."

Until recently, Mr. Phillips was Chief Financial Officer and Senior Vice President of Corporate Development at G1 Therapeutics, Inc., where, among other achievements, he was instrumental in raising over USD 300 million in multiple equity financings. Before that, he served as Senior Vice President, Chief Financial Officer and Treasurer of vaccine company, Novavax, Inc., where he helped to raise more than USD 850 million in various financings to support the company's late-stage clinical programs. Prior, Mr. Phillips was Senior Vice President and Chief Financial Officer of Micromet, Inc., which, during his tenure, was acquired by Amgen Inc. for approximately USD 1.2 billion. Mr. Phillips's exposure to venture capital came earlier, while serving as a Managing Director at Vector Fund Management, focused on investments in late-stage life sciences companies, and during his time as Biotechnology Analyst and Director of Venture Investments at Invesco, where he held primary coverage responsibility for the universe of publicly traded biotechnology companies, while managing the firm's private equity investing, with a focus on life sciences.

Mr. Phillips has served on the boards of over a dozen public and private life sciences companies. He earned a Bachelor of Arts in economics from the University of Colorado at Boulder.

About Immunic, Inc.Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORt; and IMU-856 targets the restoration of the intestinal barrier function. Immunic's lead development program, IMU-838, is in phase 2 clinical development for relapsing-remitting multiple sclerosis and ulcerative colitis, with an additional phase 2 trial planned in Crohn's disease. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at the Mayo Clinic. For further information, please visit: http://www.immunic-therapeutics.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's clinical and preclinical pipeline activities and the structure and composition of its board. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Item 1A. Risk Factors," in the company's Current Report on Form 8-K filed on July 17, 2019, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov or ir.immunic-therapeutics.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information

Immunic, Inc.Jessica BreuManager IR and Communications+49 89 250 0794 69jessica.breu@immunic.de

Or

Rx Communications GroupMelody Carey+1-917-322-2571immunic@rxir.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/immunic-inc-expands-board-of-directors-with-appointment-of-biotechnology-executive-barclay-a-phillips-300960819.html

SOURCE Immunic, Inc.

Read more from the original source:
Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips - P&T Community

A few months ago, I attended a forum on the politics and economics of disability. My impression was that the audience consisted mainly of people with disabilities -- an impression that has changed with time. Whatever the proportions may actually have been, my judgment was probably skewed by self-consciousness, and not just the usual awkwardness of finding a seat after the presentation was well underway. It had taken root long before I got to the room.

"Able-bodied" and "disabled" are categories that function in society at large as necessary and common-sensical, and they are weighted such that the first is posited as normal and predominant, and as such effectively invisible, while the other is an exceptional condition, making it, oddly, both conspicuous and ignorable as circumstances may dictate. With hindsight I am not at all sure more people at the talk had wheelchairs or canes than were present at other talks I attended at the conference. Besides, not every disability involves such a clear marker.

But since disability itself was the topic of the hour, the fact that I did not need any such assistance registered much more sharply than it ordinarily would. Eyeglasses didn't count. Experiential norms prevailing outside the room were not taken for granted, as became even more clear following the speaker's presentation. A number of people pointed out that no American Sign Language interpreter was present. Somehow I had not noticed. Not noticing certain things is a luxury you generally aren't even aware of enjoying.

As binary oppositions go, "able-bodied/disabled" proves much less stable than it appears. It's not just that the most gifted athlete or graceful dancer may be one bullet or automobile accident away from an irrevocable change in status. As mentioned, wearing glasses allows me to function as fully able, but they are a prosthesis for the lenses in my eyes, quite as much a wheelchair is for a paraplegic's legs. And the process of aging has a way of erasing the bright line between ability and its malfunctions. Time is not on the side of the able-bodied. With aging, the binary opposition runs right through the brain, so to speak. Jokes about "having a senior moment" acknowledge (and deflect) this reality. Our long-term command of the powers of attention and memory is contingent at best.

One of the things the reader can take away from George Estreich's Fables and Futures: Biotechnology, Disability, and the Stories We Tell Ourselves (MIT Press) is a heightened sense of how damaging it can be to think of "the disabled" in terms of a distinction between "us" and "them." An instructor in writing at Oregon State University, Estreich is also the author of The Shape of an Eye: A Memoir, about raising his daughter Laura, who has Down syndrome. I haven't read it, but she reappears throughout Fables and Futures without that making the book a memoir, exactly.

"Writing about Laura has its complications," Estreich notes. "For each sentence, I could add a page of narrative caveats, a fine print to govern the legal interpretation of anecdote: 'This positive description is not meant to inspire Though the author has strong opinions on a range of social issues, he declines to weaponize his daughter in their service. Laura is not an example in an argument She is a person, and by describing her the author intends to suggest what she is like and raise questions about the world she enters. This work is related to, yet different from, his work as a parent, which is to help her find, in every sense, her place.' Behind these caveats is the wish to control interpretation, and behind that vain hope is, in no particular order, a writer's ego, a father's protectiveness, and a deep familiarity with the average Internet comment section."

That is quite a few knives to juggle at the same time. And the list does not even include the issue on which Estreich concentrates here: the advancing biotechnology of prenatal testing and genetic editing. The book is a sort of intellectual travelogue, the author thinking his way across a landscape that is changing faster than it can be captured in concepts. When he attends an event in New Orleans that doubles as a professional conference for genetic counselors and a trade show for biotech companies, he notes, "The uneasy tension between old and new brought on by biotech: the more artifice the project requires, the more its advocates retail images of naturalness and purity." The quest to render the woolly mammoth "de-extinct" coexists with strong an implicit and largely unacknowledged strain of 21st-century eugenics.

Given the murderous consequences of one especially vehement form, we tend to think of eugenics as prone to goose-stepping. But a tangent from the memory of his daughter's participation in a county fair leads Estreich back to the era of Better Babies and Fitter Families contests at Midwestern state fairs, in which whole families underwent exams and answered questionnaires to determine which was freest from inherited defects. "If human improvement is on stage," he writes, "disability-based metaphors are usually skulking in the wings."

The author's worry -- which is also a father's worry -- concerns the possible cascade of effects of "our rapidly increasing, fine-grained knowledge of genetic variation." A culture that takes technological development as inevitable is dangerous enough, to itself and others, without having the option of decision making that "invoke[s] abnormality, a word capacious enough to hold everything and everyone considered different and undesirable." Estreich is uncommonly adept at presenting both experiences and ideas in layers, without the structure itself becoming either unmanageable or distracting. Anyone who reads it should expect the wheels in their head to keep spinning for a while afterward.

Read the original post:
Review of George Estreich, 'Fables and Futures: Biotechnology, Disability, and the Stories We Tell Ourselves' (opinion) - Inside Higher Ed

Biotechnology-Based Chemical Market are items gotten from natural roots, for example, feedstock, plants, harvests, trees, and organic waste. This will benefit the reports users, that evaluates their position in the market as well as create effective strategies in the near future. They are a reasonable option in contrast to traditional synthetic concoctions and will assume a noteworthy job in decreasing the dependence on non-renewable energy sources. This can prompt diminished carbon discharge levels and keep up the biological parity. Lignocellulose is the most generally accessible crude material utilized for the creation of biofuels.

The report of CMFE Insights the Industrial substance application is foreseen to command the worldwide Biotechnology-Based Chemical Market growing CAGR of +16% during forecast period.

The report shields the development activities in the Biotechnology-Based Chemical which includes the status of marketing channels available, and an analysis of the regional export and import. The report ends with an inference for the global market as it was in industry. Researchers of this research report throw light on demand-supply chaining in the market. The forward-disapproved of people supporting the improvement of bio-based synthetic substances, specialists have been growing new sources and applications for Biotechnology-Based Chemical Market around the globe, delivering promising outcomes.

Request A sample copy of this report at https://www.cmfeinsights.com/request-sample.php?id=46666

The Report includes Several Company Profiles of who are market key players:

Biotechnology-Based Chemical Market by region:

The significant sorts of biotechnology are red, green, white, and blue biotechnology. Red biotechnology includes medicinal procedures, white biotechnology which is otherwise called dark biotechnology is primarily utilized in mechanical procedures, green biotechnology includes agrarian biotech procedures and blue biotechnology involves marine and amphibian procedures. Biotechnology-Based Chemical Market has wide applications crosswise over modern territories, for example, horticulture, prescription, sustenance generation, human services, and yield creation.

Get up to 40% Discount on this report at https://www.cmfeinsights.com/ask-for-discount.php?id=46666

Market by Type

Market by Application

The application, of worldwide Biotechnology-Based Chemical Market compounds is isolated into mechanical synthetic compounds, agribusiness, pharmaceuticals, and others. Leading key players have been profiled to get a clear insight into the businesses on the basis of successful strategies of the top level companies. Along with this, it also offers competitive significance among the several traders by presenting the facts and figures of market shares.

In this study, the years considered to estimate the market size of Biotechnology-Based Chemical Market are as follows:

About Us : CMFE Insights caters to clients needs by elucidating the power of innovation, thus thriving on business innovations. Our mission is to guide global businesses through our comprehensive market research reports. Through our infrastructural competence of digital transformations, we orchestrate escalated market efficiency for our clients by presenting them with capable growth opportunities in the global market scenario. Through the experienced eye of our research associates we help our clients to envision a flourishing future. CMFE Insights techniques is a perfect blend of both qualitative and quantitative modes, on basis of which we provide our clients with syndicated research reports to further enhance their strategic organizational decisions. CMFE Insights helps clients to build a pragmatic future in the innovative market industry.

Contact :

CMFE Insights

Jay S

+44 7537 121342

Office 271

321 323 High Rd

Chadwell Heath

RM6 6AX UK

sales@cmfeinsights.com

http://www.cmfeinsights.com

Read more:
Exclusive Research on Biotechnology-Based Chemical Market by CMFE Insights with Leading Players Sarnia-Lambton Research, UK and Norway business...

From the gene-editing powers of CRISPR-Cas9 to the creation of clean meat technologies, the biotechnology field continues to top one new development with another in rapid succession, and because of this innovative velocity, there is an increasing need for biotech leaders who understand both the science and the business of this ever-expanding field.

Where do women fit into this process? Do they face the same gender parity issues that they confront in other areas of science, technology, engineering and math, or STEM? What challenges should they prepare for as they launch a career in biotech?

A top-notch panel of scientists and entrepreneurs came together on Sept. 26, 2019, to answer these questions at the Katz School of Science and Healths first fall event for Women in Bio. Leading Biotech and Healthcare Organizations from Early to Late Stage, was co-organized by Dr. Rana Khan, director of the MS in Biotechnology Management and Entrepreneurship Program at the Katz School, and the New York Chapter of Women in Bio, the national organization for women in life sciences.

Panelists included Dr. Christina Brennan, vice president of clinical research, Northwell Health; Dr. Jeanne Magram, chief scientific officer, Quentis Therapeutics; Dr. Sandra Saldana, CEO and co-founder of Alva Health and adjunct professor at Yeshiva University; and Dr. Mani Mohindru, CFO and chief strategy officer at Cara Therapeutics.

The event was a resounding success with great speakers and engaged attendees, one of whom described it as a difference-making experience. It was empowering to sit in a roomful of professional women, in top roles, opening their hearts about the challenges they are going through. I came away with two new connections that are meaningful to my career. Thank you, YU, for hosting such a memorable event.

Original post:
Women in Biotech: Katz Event Explores the Rewards and Challenges of a Career in Biotechnology - Yu News

TEL AVIV, Israel, Nov. 19, 2019 /PRNewswire/ --Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the third quarter ended September 30, 2019 and provided a corporate update.

Recent Highlights

"Our clinical and regulatory teams remained focused during the third quarter and the more recent positive developments position us to achieve our goals, both in the U.S. and Israel," commented Dr. Shai Yarkoni, Chief Executive Officer. "In the U.S., the IND approval is a significant achievement and represents our first-ever FDA IND in the U.S., with Washington University School of Medicine. In Israel, our Phase 1/2 clinical study of ApoGraft is progressing slowly and we expect to complete the recruitment around the end of the year."

"With our prudent use of cash during the third quarter and the anticipated cash usage needs over the coming quarters, we continue to believe we have the resources to execute our clinical and regulatory plans for the foreseeable future," said Eyal Leibovitz, Chief Financial Officer.

ThirdQuarter 2019 Financial Results:

*For the convenience of the reader, the amounts above have been translated from NIS into U.S. dollars, at the representative rate of exchange on September 30, 2019 (U.S. $1 = NIS 3.482).

Strategic Review Progress Update

On May 16, 2019, the Company disclosed that it commenced plans to explore strategic alternatives to maximize shareholder value. Potential strategic alternatives that may be evaluated include, but are not limited to, an acquisition, merger, business combination, including in other business fields than the Company's in-licensing, or other strategic transaction involving the Company or its assets. The Company continues to evaluate business development opportunities and will keep investors informed as they mature or warrant investor disclosure.

About Cellect Biotechnology Ltd.

Cellect Biotechnology (APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.

The Company's technology is expected to provide researchers, clinical community and pharma companies with the tools to rapidly isolate stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; or maintain its current operations; uncertainties involving any strategic transaction the Company may decide to enter into as the result of its current efforts to explore new strategic alternatives; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; and the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2018 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the SEC.

Cellect Biotechnology Ltd

Consolidated Statement of Operation

Convenience

translation

Nine months

ended

Nine months ended

Three months ended

September 30,

September 30,

September 30,

2019

2019

2018

2019

2018

Unaudited

Unaudited

U.S. dollars

NIS

(In thousands, except share and per

share data)

Research and development expenses

2,743

9,551

9,473

2,465

4,125

General and administrative expenses

2,249

7,832

11,001

2,768

3,929

Operating loss

4,992

17,383

20,474

5,233

8,054

Financial expenses (income) due to warrants exercisable into shares

(2,303)

(8,020)

(2,935)

(910)

(1,320)

Other financial expenses (income), net

393

1,369

(1,177)

489

64

Total comprehensive loss

3,082

10,732

16,362

4,812

6,798

Loss per share:

Basic and diluted loss per share

0.015

0.051

0.127

0.021

0.052

Basic and diluted loss per ADS

0.30

1.02

2.54

0.42

1.04

Weighted average number of shares outstanding used to compute basic and diluted loss per share

208,771,303

208,771,303

129,139,278

224,087,799

130,192,799

Cellect Biotechnology Ltd.

Consolidated Balance Sheet Data

ASSETS

Convenience

translation

September 30,

September 30,

December 31,

2019

2019

Here is the original post:
Cellect Biotechnology Reports Third Quarter 2019 Financial and Operating Results - PRNewswire

The global Food Biotechnology industry research report offers a detailed analysis of the current status of the market 2019. This extensive Global Food Biotechnology Market research report contains a brief on industry trends that can guide the business operators in the industry to get an idea of the market and strategize for their business development accordingly. The research report studies the market size, Food Biotechnology industry share, growth rate, key segments, CAGR (%) and key drivers. At the start, the report offers a basic introduction to the Food Biotechnology market including definitions, applications, classifications and industry chain analysis. The study serves as the international Food Biotechnology market consist of development past, competitive landscape study, and advancement states of Food Biotechnology in major geographical regions.

Get a sample of the report from https://www.orbisreports.com/global-food-biotechnology-market/?tab=reqform

Secondly, Food Biotechnology manufacturing processes and cost study are discussed as well as development policies and plans are also included. This Food Biotechnology market research report also gives the data on import/send out, supply-demand, and Food Biotechnology consumption values along with cost, revenue and gross margin by worldwide regions. This Food Biotechnology report will surely help you to understand and apply the ideas and guide you in making strong decisions. The world Food Biotechnology industry was valued in 2019 is XX Mn US$ and is evaluates to be XX Mn US$ forecasting to 2024, with a perspective CAGR of X.X %.

Food Biotechnology Market Major Manufacturers:

ABS GlobalArcadia BiosciencesAquaBounty TechnologiesBASF Plant ScienceBayer CropScience AGCamson Bio Technologies LtdDow AgroSciences LLCDuPont PioneerEvogene LtdHy-Line InternationalKWS GroupMonsantoOrigin Agritech LimitedSyngenta AG

The aim of Food Biotechnology report is to give an idea to the readers in making firm business decisions based on market latest trends and upcoming market improvement estimates in forecast years. The study contains Food Biotechnology market contributors including vendors/traders, buyers/distributors/, suppliers/sellers. Their Food Biotechnology marketing strategies are also provided. Global Food Biotechnology report analyses the historical data regarding the market growth, Food Biotechnology market scope and also offers the current and Food Biotechnology market upcoming information. The study of major growth opportunities and challenges to the Food Biotechnology market is included.

Food Biotechnology Market Types Are:

Transgenic CropsSynthetic Biology Derived Products

Food Biotechnology Market Applications Are:

AnimalsPlantsOther

For more Information or Any Query Visit: https://www.orbisreports.com/global-food-biotechnology-market/?tab=discount

The worldwide Food Biotechnology industry report offers a thorough study of the Food Biotechnology market. The report Food Biotechnology focuses industry vision from experts. An in-depth segmentation of the Food Biotechnology industry has been provided in the report. Moreover, the world Food Biotechnology industry report also includes the sub-segments. The key sector, the emerging and leading sectors, together with their growth stats have been cited in the Food Biotechnology market report.

After a brief outlook of the global Food Biotechnology market, the report studies the market dynamics. The major drivers helping Food Biotechnology market growth and the major constraints inhibiting Food Biotechnology market growth are provided in this report. In addition, the Food Biotechnology industry report also gives the threats and challenges that companies in the Food Biotechnology market need to focus on. The most influencing trends that will give the structure the Food Biotechnology market during the forecasting prospect are also provided in this report. Furthermore, the report expands on the regulatory scheme governing the Food Biotechnology market and its possible effects on the market in the foreseeable horizon.

The insight analysis on Food Biotechnology research report provides:

The evaluated Food Biotechnology growth rate together with size and market share over the forecast period 2019-2024. The primary factors estimated to drive the Food Biotechnology Market for the forecasting period 2019-2024. The major Global Food Biotechnology market regulatory bodies and what has been their business expanding strategy for leading so far. Influential trends shaping the growth probabilities of the Food Biotechnology Market.

In-depth and complete business outlook, Food Biotechnology market revenue study, business expansion strategies, and SWOT analysis of the major leading players have been served in the report. Vendors in the Worldwide Food Biotechnology market are focusing to explore their operations to developing regions. More, companies in the Food Biotechnology market are concentrating on innovation and standing their Food Biotechnology products at competitive prices. A detailed analysis of Food Biotechnology supply chain in the report will help readers to understand Food Biotechnology market clearly.

Click here to see full TOC https://www.orbisreports.com/global-food-biotechnology-market/?tab=toc

Read the original here:
Food Biotechnology Market 2019| 2019 Applications, Types and Growing Trends, Share 2024 - Eastlake Times

The 74 rating InvestorsObserver gives to Jounce Therapeutics Inc (JNCE) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 96 percent of stocks in the Biotechnology industry, JNCEs 74 overall rating means the stock scores better than 74 percent of all stocks.

Click Here to get the full Stock Score Report on Jounce Therapeutics Inc (JNCE) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Jounce Therapeutics Inc (JNCE) stock is trading at $5.81 as of 10:05 AM on Thursday, Nov 14, a rise of $0.22, or 3.86% from the previous closing price of $5.59. The stock has traded between $5.62 and $6.19 so far today. Volume today is 195,167 compared to average volume of 163,071.

To see InvestorsObservers Sentiment Score for Jounce Therapeutics Inc click here.

Read the original post:
Where Does JNCE Stock Rank in the Biotechnology Industry? - InvestorsObserver